Characterisation and outcome of RAC1 mutated melanoma

Abstract

Background Activating hot spot R29S mutations in RAC1, a small GTPase influencing several cellular processes including cell proliferation and cytoskeleton rearrangement, have been reported in up to 9% of sun-exposed melanomas. Clinical characteristics and treatment implications of RAC1 mutations in melanoma remain unclear. Methods We investigated the largest set (n = 64) of RAC1 mutated melanoma patients reported to date, including a retrospective single institution cohort (n = 34) from the University Hospital Essen and a prospective multicentre cohort (n = 30) from the translational study Tissue Registry in Melanoma (TRIM; CA209-578), for patient and tumour characteristics as well as therapy outcomes. Results From 3037 sequenced melanoma samples screened RAC1 mutations occurred in ∼2% of samples (64/3037). The most common RAC1 mutation was P29S (95%, 61/64). The majority of tumours had co-occuring MAP kinase mutations (88%, 56/64); mostly activating NRAS (47%, 30/64) mutations, followed by activating BRAF (28%, 18/64) and NF1 (25%, 16/64) mutations. RAC1 mutated melanomas were almost exclusively of cutaneous origin (84%, 54/64) or of unknown primary (MUP, 14%, 9/64). C > T alterations were the most frequent mutation type identified demonstrating a UV-signature for RAC1 mutated melanoma. Most patients with unresectable disease (39) received immune checkpoint inhibitors (ICI) (77%, 30/39). Objective response rate of first-line treatment in patients with stage III/IV disease was 21%; median overall survival was 47.8 months. Conclusions RAC1 mutated melanomas are rare, mostly of cutaneous origin and frequently harbour concomitant MAP kinase mutations, particularly in NRAS. Patients with advanced disease benefit from systemic treatment with ICI.

Publication
European Journal of Cancer
Georg C. Lodde
Georg C. Lodde
Clinician Scientist

My research interests include Dermatology, Medical Research, and Digitalization.

Wolfgang Galetzka
Wolfgang Galetzka
Researcher in the first cohort

My research interests include Deep Learning, Computer Vision, Radiomics, and Explainable AI.

Elisabeth Livingstone
Elisabeth Livingstone
Principal Investigator

My research interests include Medical Research, Dermatology, and Digitalization.

Dirk Schadendorf
Dirk Schadendorf
Principal Investigator

My research interests include Dermatology, Medical Research, and Digitalization.

Next
Previous

Related